Therapy with acetylsalicylic acid does not interfere with oral surgery

• Authors: Damian Dudek , Krzysztof Helewski , Grzegorz Wyrobiec , Marzena Harabin-Słowińska , Grażyna Kowalczyk-Ziomek , Małgorzata Żaba , Piotr Wesołowski , Tomasz Stawski , Romuald Wojnicz
• Languages of publication: EN

Abstracts

EN

The acetylsalicylic acid (ASA) treatment is widespread therapeutic strategy in cardiology clinics. On the other hand, patients with heart diseases represent a significant group of cases in dental clinics. Accordingly, we studied the local hemostatic thrombus formation after dental tooth extractions (n=47) and other oral surgery treatment (n=13) in 60 patients with heart disease being on ASA therapy without drug discontinuation. In the control group free of ASA therapy it was: (n=24) and (n=6), respectively. In all studied patients, the aggregative activity of blood platelets by PFA-100 analyzer was assessed. It was found that 61.7% patients treated with ASA presented inhibition of platelets aggregation. Unexpectedly, in 35% of such patients, platelet aggregation function remained unchanged. In the control group, normal platelet aggregation was found in all subjects. It has been shown that ASA therapy has neutral effects on both thrombus formation and pain complications in patients with heart disease underwent tooth extraction and other oral surgery. Thus discontinuation of ASA therapy before surgery seems to be weakly validated.

Keywords

EN

Platelets; Acetylsalicylic acid; Oral surgery; Dental tooth extraction

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2013
• Volume: 8
• Issue: 4
• Pages: 392-397

Dates

published

1 - 8 - 2013

online

12 - 6 - 2013

Contributors

author

Damian Dudek

author

Krzysztof Helewski

• Department of Histology and Embryology, Medical University of Silesia in Katowice, Jordana Str 19, Zabrze, 41-808, Poland

author

Grzegorz Wyrobiec

• Department of Histology and Embryology, Medical University of Silesia in Katowice, Jordana Str 19, Zabrze, 41-808, Poland

author

Marzena Harabin-Słowińska

• Department of Histology and Embryology, Medical University of Silesia in Katowice, Jordana Str 19, Zabrze, 41-808, Poland

author

Grażyna Kowalczyk-Ziomek

• Department of Histology and Embryology, Medical University of Silesia in Katowice, Jordana Str 19, Zabrze, 41-808, Poland

author

Małgorzata Żaba

• Department of Histology and Embryology, Medical University of Silesia in Katowice, Jordana Str 19, Zabrze, 41-808, Poland

author

Piotr Wesołowski

• Department of Dental Surgery, Medical University of Warsaw, Nowogrodzka Str 59, pawilon 11b, Warszawa, 02-006, Poland

author

Tomasz Stawski

• Department of Surgery, Municipal Hospital, Chełmońskiego Str. 28, Jaworzno, 43-600, Poland

author

Romuald Wojnicz

• Department of Histology and Embryology, Medical University of Silesia in Katowice, Jordana Str 19, Zabrze, 41-808, Poland

References

• [1] Kośmicki M., Kwas acetylosalicylowy i inne leki przeciwpłytkowe i przeciwkrzepliwe w leczeniu choroby niedokrwiennej serca, Przew. Lek., 2001, 10, 34–44, (in Polish)
• [2] Born G., Patrono C., Antiplatelet drugs, Br. J. Pharmacol., 2006, 147, S241–S251 http://dx.doi.org/10.1038/sj.bjp.0706401[Crossref]
• [3] Patrono C., Coller B., Dalen J.E., et al., Plateletactive drugs: the relationships among dose, effectiveness, and side effects, Chest., 2001, 119, 39S–63S http://dx.doi.org/10.1378/chest.119.1_suppl.39S[Crossref]
• [4] Patrono C., Coller B., FitzGerald G.A., Hirsh J., Roth G., Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, Chest., 2004, 126, 234S–264S http://dx.doi.org/10.1378/chest.126.3_suppl.234S[Crossref]
• [5] Hankey G.J., Eikelboom J.W., Antiplatelet drugs, Med. J. Aust., 2003, 178, 568–574
• [6] Hankey G.J., Eikelboom J.W., Aspirin for the primary prevention of cardiovascular events, Med. J. Aust., 2002, 177, 343–344
• [7] Golański R., Watała C., Bitner M., Iwaszkiewicz A., Zasłonka J., Golański J., Ocena skuteczności antyagregacyjnego działania kwasu acetylosalicylowego u chorych po bezpośredniej rewaskularyzacji mięśnia sercowego, Kardiochir. Torakochir. Pol., 2004, 1, 116–122, (in Polish)
• [8] Howard P.A., Aspirin resistance, Ann. Pharmacother., 2002, 36, 1620–1624 http://dx.doi.org/10.1345/aph.1C013[Crossref]
• [9] Weber A.A., Zimmermann K.C., Meyer-Kichrath J., Schrör K., Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance, Lancet, 1999, 353, 900 http://dx.doi.org/10.1016/S0140-6736(99)00498-5[Crossref]
• [10] Halushka M.K., Halushka P.V., Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2?, Circulation., 2002, 105, 1620–1622 http://dx.doi.org/10.1161/01.CIR.0000015422.86569.52[Crossref]
• [11] Smout J., Stansby G., Aspirin resistance, Br. J. Surg., 2002, 89, 4–5 http://dx.doi.org/10.1046/j.0007-1323.2001.01971.x[Crossref]
• [12] Rdzanek A., Rdzanek H., Pietrasik A., Filipiak K.J., Przeciwpłytkowe działanie kwasu acetylosalicylowego - czy wszyscy pacjenci reagują tak samo?, Stand. Med., 2004, 5, 605–610, (in Polish)
• [13] Golański J., Chiżyński K., Golański R., Watała C., Zastosowanie analizatora funkcji płytek PFA-100 oraz metody agregacji we krwi pełnej do oceny wrażliwości płytek krwi na działanie kwasu acetylosalicylowego (aspiryny). Czy możliwa jest wiarygodna laboratoryjna weryfikacja leczenia przeciwpłytkowego?, Pol. Arch. Med. Wewn., 2000, 104, 355–361, (in Polish)
• [14] Keresztes P.A., Tazbir J., The PFA-100: analysis and interpretation of a platelet function measurement, J. Cardiovasc. Nurs., 2005, 20, 405–407 [Crossref]
• [15] Haubelt H., Anders C., Hellstern P., Can platelet function tests predict the clinical efficacy of aspirin?, Semin. Thromb. Hemost., 2005, 31, 404–410 http://dx.doi.org/10.1055/s-2005-916674[Crossref]
• [16] Coakley M., Self R., Marchant W., Mackie I., Mallett S.V., Mythen M., Use of the platelet function analyzer (PFA-100) to quantify the effect of low dose aspirin in patients with ischaemic heart disease, Anaesthesia., 2005, 60, 1173–1178 http://dx.doi.org/10.1111/j.1365-2044.2005.04291.x[Crossref]
• [17] Hayward C.P., Harrison P., Cattaneo M., Ortel T.L., Rao A.K., Platelet function analyzer PFA-100 closure time in the evaluation of platelet disorders and platelet function, J. Thromb. Haemost., 2006, 4, 312–319 http://dx.doi.org/10.1111/j.1538-7836.2006.01771.x
• [18] Cieślik-Bielecka A., Pelc R., Cieślik T., Oral surgery procedures in patients on anticoagulants. Preeliminary report, Kardiol. Pol., 2005, 63, 137–140
• [19] Hemelik M., Wahl G., Kessler B., Zahnextraktionen unter Medikation mit Acetylsalicylsaure (ASS), Mund. Kiefer. Gesichtschir., 2006, 10, 3–6 http://dx.doi.org/10.1007/s10006-005-0666-9[Crossref]
• [20] Ardekian L., Gaspar R., Peled M., Brener B., Laufer D., Does low-dose aspirin therapy complicate oral surgical procedures?, J. Am. Dent. Assoc., 2000, 131, 331–335
• [21] Madan G.A., Madan S.G., Madan G., Madan A.D., Minor oral surgery without stopping daily low-dose aspirin therapy: a study of 51 patients, J. Oral. Maxillofac. Surg., 2005, 63, 1262–1265 http://dx.doi.org/10.1016/j.joms.2005.05.164[Crossref]
• [22] Thomason J.M., Seymour R.A., Murphy P., Brigham K.M., Jones P., Aspirin-induced post-gingivectomy haemorrhage: a timely reminder, J. Clin. Periodontol., 1997, 24, 136–138 http://dx.doi.org/10.1111/j.1600-051X.1997.tb00480.x[Crossref]
• [23] Lemkin S.R., Billesdon J.E., Davee J.S., Leake D.L., Kattlove H.E., Aspirin induced oral bleeding: correction with platelet transfusion. A reminder, Oral. Surg. Oral Med. Oral Pathol., 1974, 37, 498–501 http://dx.doi.org/10.1016/0030-4220(74)90278-3[Crossref]
• [24] McGaul T., Postoperative bleeding caused by aspirin, J. Dent., 1978, 6, 207–209 http://dx.doi.org/10.1016/0300-5712(78)90243-9[Crossref]
• [25] Mak S., Amoroso P., Stop those antiplatelet drugs before surgery!, BJU. Int., 2003, 91, 593–594 http://dx.doi.org/10.1046/j.1464-410X.2003.04209.x[Crossref]
• [26] Richardson J.D., Cocanour C.S., Kern J.A., et al., Perioperative risk assessment in elderly and high-risk patients, J. Am. Coll. Surg., 2004, 199, 133–146 http://dx.doi.org/10.1016/j.jamcollsurg.2004.02.023[Crossref]
• [27] Bochenek A., Wilczyński M., Leki przeciwpłytkowe - krwawiący problem kardiochirurga, Kardiol. Pol., 2006, 64, 1329–1331, (in Polish)
• [28] Bybee K.A., Powell B.D., Valeti U., et al., Preoperative aspirin therapy is associated with improved postoperative outcomes in patients undergoing coronary artery bypass grafting, Circulation., 2005, 112, I-286–292
• [29] Samama C.M., Bastien O., Forestier F., et al., Antiplatelet agents in the perioperative period: expert recommendations of the French Society of Anesthesiology and Intensive Care (SFAR) 2001: summary statement, Can. J. Anaesth., 2002, 49, S26–S35
• [30] Lewandowski B., Maresch-Lewandowska M., Surgicell-fibrillar in the prevention of post extraction bleeding in patients receiving prophylactic aspirin, Mag. Stomatol., 2005, 1, 20–23, (in Polish)

Identifiers

DOI

10.2478/s11536-013-0176-3